Improvement in Survival and Cardiac Metabolism After Gene Transfer of Sarcoplasmic Reticulum Ca\textsuperscript{2+}-ATPase in a Rat Model of Heart Failure

Federica del Monte, MD, PhD; Eric Williams, BS; Djemal Lebeche, PhD; Ulrich Schmidt, MD, PhD; Anthony Rosenzweig, MD; Judith K. Gwathmey, VMD, PhD; E. Douglas Lewandowski, PhD; Roger J. Hajjar, MD

**Background**—In heart failure, sarcoplasmic reticulum (SR) Ca\textsuperscript{2+}-ATPase (SERCA2a) activity is decreased, resulting in abnormal calcium handling and contractile dysfunction. We have previously shown that increasing SERCA2a expression by gene transfer improves ventricular function in a rat model of heart failure created by ascending aortic constriction.

**Methods and Results**—In this study, we tested the effects of gene transfer of SERCA2a on survival, left ventricular (LV) volumes, and metabolism. By 26 to 27 weeks after aortic banding, all animals developed heart failure (as documented by >25% decrease in fractional shortening) and were randomized to receive either an adenovirus carrying the SERCA2a gene (Ad.SERCA2a) or control virus (Ad.βgal-GFP) by use of a catheter-based technique. Sham-operated rats, uninfected or infected with either Ad.βgal-GFP or Ad.SERCA2a, served as controls. Four weeks after gene transfer, survival in rats with heart failure treated with Ad.βgal-GFP was 9%, compared with 63% in rats receiving Ad.SERCA2a. LV volumes were significantly increased in heart failure (0.64±0.05 versus 0.35±0.03 mL, \(P<0.02\)). Overexpression of SERCA2a normalized LV volumes (0.46±0.07 mL) in the failing hearts. \(3^P\) NMR analysis showed a reduced ratio of phosphocreatine to ATP content in failing + Ad.βgal-GFP compared with sham + Ad.βgal-GFP (0.82±0.13 versus 1.38±0.14, \(P<0.01\)). Overexpression of SERCA2a in failing hearts improved the phosphocreatine/ATP ratio (1.23±0.28).

**Conclusions**—In this study, we show that unlike inotropic agents that improve contractile function at the expense of increased mortality and worsening metabolism, gene transfer of SERCA2a improves survival and the energy potential in failing hearts. (Circulation. 2001;104:1424-1429.)

**Key Words:** gene therapy ■ heart failure ■ calcium ■ excitation ■ contractility

In cardiac muscle, both contraction and relaxation are intimately dependent on the function of the sarcoplasmic reticulum (SR) Ca\textsuperscript{2+}-ATPase (SERCA2a) pump, which is regulated by phospholamban. In congestive heart failure, deficiency in SERCA2a results in abnormal calcium handling and diminished contraction.\(^1,2\) In addition, a decrease in phosphorylation of phospholamban has been reported in failing hearts, along with an increase in the phospholamban/SERCA2a ratio, contributing to the contractile dysfunction in heart failure.\(^3,4\) These results are consistent with the model that a decrease in SERCA2a levels alters intracellular calcium homeostasis and contributes to contractile dysfunction in failing hearts.

Recently, we showed that restoration of SERCA2a to control levels in isolated failing human cardiomyocytes improved contraction and relaxation by correcting calcium handling.\(^5\) Furthermore, in an animal model of heart failure, adenoviral gene transfer of SERCA2a improved contractile function in vivo, demonstrating the importance of SERCA2a as a therapeutic target.\(^6\) Pharmacological agents that increase contractility, however, have been shown to worsen survival in patients with heart failure and to increase the energetic demand.\(^7\) The heart requires a continuous supply of energy in the form of ATP by mostly oxidative metabolism, with the major energy reserve molecule represented by phosphocreatine (PCr).\(^8,9\) In the normal heart, although the majority of the energy consumption is due to cross-bridge cycling, relaxation requires an energy expenditure of 15% to remove Ca\textsuperscript{2+} from the cytoplasm. This high level of energy required by SERCA2a reaction is directly related to the magnitude of

Received March 22, 2001; revision received June 1, 2001; accepted June 7, 2001.

From the Cardiovascular Research Center and the Cardiology Division, Massachusetts General Hospital (F.D., E.W., D.L., U.S., A.R., R.J.H.), and Harvard Medical School (J.K.G.), Boston, Mass; and the Department of Physiology and Biophysics, College of Medicine, University of Illinois at Chicago (E.D.L.).

Correspondence to Roger J. Hajjar, MD, Cardiovascular Research Center, Massachusetts General Hospital, 149 13th St, CNY-4, Charlestown, MA 02129. E-mail hajjar@cvrc.mgh.harvard.edu

© 2001 American Heart Association, Inc.

Circulation is available at http://www.circulationaha.org

1424
the Ca\(^{2+}\) gradient across the SR.\(^9\) Failing hearts have a reduced PCR/ATP ratio, so less energy reserve is available for the cellular processes.

In this study, we tested the hypothesis that unlike currently used pharmacological agents that increase inotropy, reconstitution of normal levels of SERCA2a by adenoviral gene transfer would improve contractile performance as well as survival in aortic-banded rats that have developed heart failure without adversely affecting energetics.

**Methods**

**Construction of Recombinant Adenoviruses**

To construct the adenovirus containing SERCA2a cDNA, we used the method described by He et al.,\(^{10}\) whereby the backbone vector, containing most of the adenoviral genome (pAd.EASY1), is used and the recombination is performed in *Escherichia coli*. SERCA2a cDNA was subcloned into the adenoviral shuttle vector (pAd.TRACK), which uses the cytomegalovirus (CMV) long terminal repeat as a promoter. The shuttle vector used also has a concomitant green fluorescent protein (GFP) under the control of a separate CMV promoter. An adenovirus containing both \(\beta\)-galactosidase and GFP controlled by separate CMV promoters (Ad.\(\beta\)-gal-GFP) was used as a control. The adenoviruses were propagated in 293 cells. The titers of stocks used for these studies were measured by plaque assays and expressed as 3 \times 10^{11} \text{pfu/mL} for Ad.\(\beta\)-gal-GFP and 1.8 \times 10^{12} \text{pfu/mL} for Ad.SERCA2a, with particle/pfu ratios of 8:1 and 18:1, respectively. These recombinant adenoviruses were tested for the absence of wild-type virus by polymerase chain reaction of the early transcriptional unit E1.

**Experimental Protocol**

Four-week-old Sprague-Dawley rats (Charles River, Mass; 70 to 80 g) were anesthetized with pentobarbital (65 mg/kg IP) and placed on a ventilator. A suprasternal incision was made, exposing the aortic root, and a tantalum clip with an ID of 0.38 mm (Weck, Inc) was placed on the ascending aorta. Animals in the sham group underwent a similar procedure without insertion of a clip. The supravalvular incision was then closed, and the rats were transferred back to their cages. The supravalvular approach was performed because during gene delivery, a thoracotomy is necessary, and if the thorax is not opened during the initial aortic banding, adhesions are avoided when gene delivery is performed.

The animals were initially divided into 2 groups: 1 group of 45 animals with aortic banding and a second group of 42 animals that were sham-operated. Three animals in the aortic banding group did not survive the initial operation, and 2 animals in the sham-operated group did not survive. In the aortic-banded animals, we waited 26 to 28 weeks for the animals to develop left ventricular (LV) dilatation before cardiac gene transfer. In this last group as well as in the sham-operated group, 14 animals did not undergo gene transfer and were followed longitudinally. The rest of the animals underwent adenoviral gene transfer with either Ad.SERCA2a or Ad.\(\beta\)-gal-GFP.

**\(^{31}\)P NMR Measurements**

Hearts were retrogradely perfused from a 100-cm hydrostatic perfusion column with modified Krebs-Henseleit buffer (mmol/L: NaCl 116, KCl 4, CaCl\(_2\) 1.5, MgSO\(_4\) 1.2, NaHPO\(_4\) 1.2, and NaHCO\(_3\) 25, equilibrated with 95% O\(_2\)/5% CO\(_2\) at 37°C) that contained 5 mmol/L glucose in a 2-L reservoir. Hearts beat spontaneously, contracting 80 g) were anesthetized with pentobarbital (65 mg/kg IP) and placed on a ventilator. A suprasternal incision was made, exposing the aortic root, and a tantalum clip with an ID of 0.38 mm (Weck, Inc) was placed on the ascending aorta. Animals in the sham group underwent a similar procedure without insertion of a clip. The supravalvular incision was then closed, and the rats were transferred back to their cages. The supravalvular approach was performed because during gene delivery, a thoracotomy is necessary, and if the thorax is not opened during the initial aortic banding, adhesions are avoided when gene delivery is performed.

The animals were initially divided into 2 groups: 1 group of 45 animals with aortic banding and a second group of 42 animals that were sham-operated. Three animals in the aortic banding group did not survive the initial operation, and 2 animals in the sham-operated group did not survive. In the aortic-banded animals, we waited 26 to 28 weeks for the animals to develop left ventricular (LV) dilatation before cardiac gene transfer. In this last group as well as in the sham-operated group, 14 animals did not undergo gene transfer and were followed longitudinally. The rest of the animals underwent adenoviral gene transfer with either Ad.SERCA2a or Ad.\(\beta\)-gal-GFP.

**\(^{31}\)P NMR Measurements**

Hearts were retrogradely perfused from a 100-cm hydrostatic perfusion column with modified Krebs-Henseleit buffer (mmol/L: NaCl 116, KCl 4, CaCl\(_2\) 1.5, MgSO\(_4\) 1.2, NaHPO\(_4\) 1.2, and NaHCO\(_3\) 25, equilibrated with 95% O\(_2\)/5% CO\(_2\) at 37°C) that contained 5 mmol/L glucose in a 2-L reservoir. Hearts beat spontaneously, contracting...
buffer containing (in mmol/L) KCl 400, MgCl₂ 0.5, CaCl₂ 0.5, EGTA 0.5, and PIPES 25, pH 7.0. SERCA2a activity assays were carried out on the basis of a pyruvate/NADH coupled reaction as previously described. Ca²⁺ transfer (61.0 ± 8.2 vs sham LVs, as shown in Figure 2A). Adenoviral gene transfer of SERCA2a in failing hearts increased SERCA2a protein expression, restoring it to levels observed in the nonfailing hearts. Calsequestrin did not change among the different groups, nor did phospholamban. As shown in Figure 2B, tabulated ratios of SERCA2a to phospholamban and SERCA2a to calsequestrin reveal a significant decrease in failing hearts and a restoration to control levels with gene transfer of SERCA2a.

SERCA2a Activity
We measured SERCA2a activity at a calcium concentration of 10 mmol/L in the (1) sham + Ad.βgal-GFP, (2) failing + Ad.βgal-GFP, and (3) failing + Ad.SERCA2a groups. There was a decrease in maximal ATPase activity in the failing group (27.4 ± 4.9 versus 62.2 ± 12.8 mmol · mg⁻¹ · min⁻¹). Gene transfer of SERCA2a restored ATPase activity back to normal levels in the failing group 4 weeks after gene transfer (61.0 ± 8.5 mmol · mg⁻¹ · min⁻¹).

NMR Spectroscopy
Representative ³¹P NMR spectra obtained from 3 groups of rats: (1) sham + Ad.βgal-GFP, (2) failing + Ad.βgal-GFP, and (3) failing + Ad.SERCA2a, are shown in Figure 3A. These spectra show that the ratios of total amounts of PCr to ATP are lower in the failing heart than the sham heart. The integrated area for P₁ was also increased in the failing heart.

**RESULTS**

**Survival**
Figure 1 shows the survival curve for the 6 different groups studied. The sham-operated animals did not show any premature mortality. The sham-operated animals did not show any premature mortality. The sham-operated animals that were infected with either Ad.βgal-GFP or Ad.SERCA2a had early mortalities related to the surgical intervention, but then the survival curves leveled off for both sham + Ad.βgal-GFP and sham + Ad.SERCA2a. In the failing group, the noninfected animals had a survival curve that decreased steadily, and at 4 weeks the survival rate was only 18% (P < 0.005 compared with sham). In the failing + Ad.βgal-GFP group, the survival curve also decreased, and at 4 weeks the survival rate was only 9% (P < 0.001 compared with sham + Ad.βgal-GFP). In the failing + Ad.SERCA2a group, however, the survival curve was significantly improved compared with failing + Ad.SERCA2a (P < 0.001 compared with failing + Ad.βgal-GFP).

**Characterization of Animals**
After 18 weeks of aortic banding, the animals showed echocardiographic signs of LV hypertrophy, including an increase in wall thickness (both posterior and septal), an increase in posterior wall thickness, a decrease in LV dimensions, and an increase in fractional shortening, as shown in Table 1. After 26 to 27 weeks of banding, these animals had uniformly (1) small pericardial effusions, (2) pleural effusions, (3) an increase in lung weight, (4) ascites, and (5) dyspnea at rest, all indicative signs of severe heart failure. Echocardiographically, LV end-diastolic dimensions increased and fractional shortening decreased.

**TABLE 1.** Echocardiographic Measures in Rats After Sham Surgery or Aortic Banding

<table>
<thead>
<tr>
<th></th>
<th>Septum, mm</th>
<th>PW, mm</th>
<th>LVEDD, mm</th>
<th>LVESD, mm</th>
<th>FS, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham</td>
<td>14.9 ± 1.1</td>
<td>13.5 ± 1.0</td>
<td>66.8 ± 3.8</td>
<td>40.4 ± 6.0</td>
<td>40.0 ± 6.3</td>
</tr>
<tr>
<td>Aortic banding (18 weeks)</td>
<td>20.1 ± 3.9†</td>
<td>19.8 ± 2.8‡</td>
<td>61.9 ± 6.4§</td>
<td>34.0 ± 6.2‡</td>
<td>46.0 ± 8.2‡§</td>
</tr>
<tr>
<td>Aortic banding (27 weeks)</td>
<td>19.7 ± 2.8†</td>
<td>18.5 ± 2.3†</td>
<td>69.5 ± 6.3§</td>
<td>45.1 ± 6.9¶</td>
<td>36.0 ± 10.4§</td>
</tr>
</tbody>
</table>

PW indicates posterior wall thickness during diastole; LVEDD, LV diameter at end diastole; LVESD, LV diameter at end systole; and FS, fractional shortening.

*P < 0.0005 vs aortic banding (27 weeks).
†P < 0.005, ‡P < 0.005, §P < 0.05 vs sham.
The overexpression of SERCA2a in failing heart restored and normalized the content of both PCr and ATP (Figure 3B). Interestingly, we found that overexpression of SERCA2a in sham-operated animals induces a reduction in PCr/ATP ratio.

Effects of SERCA2a Overexpression on Pressure-Volume Relationship

Pressure-volume analysis was performed in a subset of animals. LV volumes were significantly increased in the failing rats (0.64 ± 0.05 versus 0.35 ± 0.03 mL, P < 0.02) and were decreased after SERCA2a gene transfer (0.46 ± 0.07 mL). The slope of the end-systolic pressure-volume relationship (Figure 4) was lower in failing hearts infected with Ad.βgal-GFP (n = 5) than in sham (n = 6), indicating a diminished state of intrinsic myocardial contractility: 450 ± 71 versus 718 ± 83 mm Hg/mL (P < 0.02). Gene transfer of SERCA2a restored the slope of the end-systolic pressure-volume relationship to control levels (691 ± 91 mm Hg/mL, Figure 4).
Effect on Morphological Parameters

As shown in Table 2, the failing hearts had a significant increase in heart weight when normalized to either tibial length or body mass. Gene transfer of SERCA2a in the failing heart did not have a significant effect on LV mass whether normalized to tibial length or body mass.

Discussion

In this study, we show that in an animal model of heart failure and contractile dysfunction, restoration of SERCA2a expression by cardiac gene transfer in vivo improves not only contractile function but also survival and cardiac energetics.

Abnormal SR Function and Cardiac Gene Transfer of SERCA2a

Impaired SERCA2a activity is one of the main characteristics associated with abnormal calcium handling in heart failure. A decrease in SERCA2a relative to phospholamban and a reduction of phosphorylation of phospholamban contribute to the contractile dysfunction in human heart failure. More recently, the ratio of the Na/Ca exchanger to SERCA2a has been shown to be increased in failing hearts and to be predictive of diastolic function in these hearts. Gene transfer of SERCA2a corrects both the SERCA2a/phospholamban ratio and the SERCA2a/Na/Ca ratio and would contribute to restoring both systolic and diastolic function.

In our study, we showed that SERCA2a protein levels were restored to normal levels in the failing hearts and that this effect was sustained for up to 4 weeks. This seemed somewhat surprising, because first-generation adenoviruses induce transient expression peaking at 7 to 10 days and disappearing after 10 days. Endogenous turnover of SERCA2a, however, is approximately 14 to 15 days in young rats and longer in older rats, which would explain the sustained levels of SERCA2a.

SERCA2a Expression and Cardiac Energetics

Decreased energy reserve via the creatine kinase reaction is a characteristic finding in both human and experimental heart failure. This decrease in energy reserve contributes to the development of contractile dysfunction in heart failure. In addition, an increase in intracellular Pi has been shown to decrease SR calcium loading and to depress calcium-induced calcium release. Local ATP regeneration by the creatine kinase system is one mechanism the cell can use to improve Ca2+ uptake by the SR in conditions in which an excessive increase in cytoplasmic [Ca2+] may have deleterious effects. Recently, Tian et al9 showed that pharmacological inhibition of creatine kinase resulted in altered energetics and induced abnormal Ca2+ handling and contractile dysfunction in the rat. In our experiments, restoring SERCA2a levels to normal induced an improvement in the ratio of PCr to ATP.

The findings of improved cardiac energetics in heart failure was somewhat surprising, because an increase in contractility by SERCA2a overexpression would be anticipated to increase ATP hydrolysis, thereby driving PCr down. Indeed, this increase in ATP hydrolysis is consistent with our observation of reduced PCr/ATP in the group of sham-operated hearts that were overexpressing SERCA2a. These results are also consistent with previous results showing that PCr/ATP was decreased in the phospholamban-deficient hearts relative to the wild-type hearts.

In heart failure, however, elevated calcium levels would increase energy demand. To maintain low levels of diastolic Ca2+, a high level of free energy released from ATP hydrolysis ([ΔGp]) is necessary. To maintain the normal Ca2+ gradient (∼10 000-fold between the cytosol and the SR), the SERCA2a reaction requires a [ΔGp] of ≥52 kJ/mol, 85% to 90% of it from ATP. Therefore, all of the ATPase reactions in cardiac myocytes, the SERCA2a reaction is the most vulnerable to a decrease in [ΔGp].

Survival After Gene Transfer: Therapeutic Implications

In this model of heart failure, SERCA2a overexpression improved parameters of inotropy and normalized contractile reserve. These effects translate into an inotropic intervention. Other inotropic interventions, however, have been shown clinically to increase mortality. There are, however, significant differences between enhancing inotropy with pharmacological agents that usually increase cAMP and gene transfer of SERCA2a. Unlike agents that increase cAMP, thereby increasing intracellular Ca2+, restoration of SERCA2a levels decreases diastolic Ca2+. Furthermore, it has been shown that sustained elevations of resting Ca2+ lead to activation of serine-threonine phosphatases, including calcineurin, inducing hypertrophy and cell death. Therefore, a decrease in diastolic Ca2+ may in effect reduce the proapoptotic and prohypertrophy signaling. Heart failure is associated with an increased incidence of ventricular arrhythmias, and triggered activity is a probable mechanism of arrhythmogenesis in heart failure. The increase in intracellular calcium secondary to SERCA2a downregulation increases the arrhythmogenic potential. Preventing an increase in intracellular calcium by overexpression of SERCA2a prevents the induction of triggered activity. Furthermore, improvement in energetics is another important finding in this study that may have a direct influence on survival.

Conclusions

Our results demonstrate that restoring SERCA2a expression can improve not only systolic and diastolic performance in

**TABLE 2. Morphometric Analyses**

<table>
<thead>
<tr>
<th>Group</th>
<th>HW/BW×10^4</th>
<th>HW/TL×10^2, g/mm</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham + Ad.βgal-GFP</td>
<td>3.7±0.3</td>
<td>44.8±4.3</td>
</tr>
<tr>
<td>Sham + Ad.SERCA2a</td>
<td>4.4±0.6</td>
<td>55.3±6.2</td>
</tr>
<tr>
<td>Failing + Ad.βgal-GFP</td>
<td>4.4±0.5*</td>
<td>50.8±4.4*</td>
</tr>
<tr>
<td>Failing + Ad.SERCA2a</td>
<td>4.3±0.4*</td>
<td>50.3±6.3*</td>
</tr>
</tbody>
</table>

HW indicates heart weight; BW, body weight; and TL, tibial length.

*p<0.05 vs Sham + Ad.GFP.
failing hearts but also survival and cardiac energetics. Furthermore, SERCA2a normalization halts the adverse remodeling that occurs with congestive heart failure. This study validates the feasibility of cardiac gene transfer in failing hearts as a therapeutic modality.

Acknowledgments

This work was supported in part by grants from the National Institutes of Health: HL-50361 and HL-57623 (Dr Hajjar); HL-59521 and HL-61557 (Dr Rosenzweig); HL-62702 (Dr Lewandowski); and a Doris Duke Charitable Foundation Clinician Scientist Award and American Federation of Aging research grant (Dr Hajjar). Dr Rosenzweig is an Established Investigator of the American Heart Association.

References


Improvement in Survival and Cardiac Metabolism After Gene Transfer of Sarcoplasmic Reticulum Ca$^{2+}$-ATPase in a Rat Model of Heart Failure

Federica del Monte, Eric Williams, Djemal Lebeche, Ulrich Schmidt, Anthony Rosenzweig, Judith K. Gwathmey, E. Douglas Lewandowski and Roger J. Hajjar

_Circulation_. 2001;104:1424-1429
doi: 10.1161/hc3601.095574

_Circulation_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2001 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/104/12/1424

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation_ is online at:
http://circ.ahajournals.org/subscriptions/